Literature DB >> 11777968

CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway.

Nongliao Zhu1, Luis M Ramirez, Rosaline L Lee, Nancy S Magnuson, Gail A Bishop, Michael R Gold.   

Abstract

The ability of CD40 signaling to regulate B cell growth, survival, differentiation, and Ig class switching involves many changes in gene expression. Using cDNA expression arrays and Northern blotting, we found that CD40 signaling increased the mRNA levels for pim-1, a protooncogene that encodes a serine/threonine protein kinase. Subsequent experiments showed that CD40 engagement also increased both Pim-1 protein levels and Pim-1 kinase activity in B cells. We then investigated the signaling pathways by which CD40 regulates Pim-1 expression and found that CD40 up-regulates Pim-1 primarily via the activation of NF-kappaB. Inhibiting the activation of NF-kappaB, either by treating cells with a chemical inhibitor, BAY11-7082, or by inducibly expressing a superrepressor form of IkappaBalpha, significantly impaired the ability of CD40 to increase Pim-1 protein levels. Because Pim-1 expression is associated with cell proliferation and survival, we asked whether this correlated with the ability of CD40 signaling to prevent anti-IgM-induced growth arrest in the WEHI-231 murine B cell line, a model for Ag-induced clonal deletion. We found that the anti-IgM-induced growth arrest in WEHI-231 cells correlated with a substantial decrease in Pim-1 levels. In contrast, culturing WEHI-231 cells with either anti-CD40 Abs or with the B cell mitogen LPS, both of which prevent the anti-IgM-induced growth arrest, also prevented the rapid decline in Pim-1 levels. This suggests that Pim-1 could regulate the survival and proliferation of B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11777968     DOI: 10.4049/jimmunol.168.2.744

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  38 in total

1.  Opposing roles of RAGE and Myd88 signaling in extensive liver resection.

Authors:  Shan Zeng; Qing Yin Zhang; Jianzhong Huang; Srinivasan Vedantham; Rosa Rosario; Radha Ananthakrishnan; Shi Fang Yan; Ravichandran Ramasamy; Ronald P DeMatteo; Jean C Emond; Richard A Friedman; Ann Marie Schmidt
Journal:  FASEB J       Date:  2011-11-10       Impact factor: 5.191

2.  Microarray analysis of Aeromonas hydrophila cytotoxic enterotoxin-treated murine primary macrophages.

Authors:  C L Galindo; A A Fadl; J Sha; A K Chopra
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

Review 3.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

4.  NFκB-Pim-1-Eomesodermin axis is critical for maintaining CD8 T-cell memory quality.

Authors:  Karin M Knudson; Curtis J Pritzl; Vikas Saxena; Amnon Altman; Mark A Daniels; Emma Teixeiro
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

5.  Induction of microRNA-1 by myocardin in smooth muscle cells inhibits cell proliferation.

Authors:  Jie Chen; Hao Yin; Yulan Jiang; Sarvan Kumar Radhakrishnan; Zhan-Peng Huang; Jingjing Li; Zhan Shi; Elisabeth P C Kilsdonk; Yu Gui; Da-Zhi Wang; Xi-Long Zheng
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-04       Impact factor: 8.311

Review 6.  The role of Pim kinase in immunomodulation.

Authors:  Zhaoyun Liu; Mei Han; Kai Ding; Rong Fu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 7.  Why target PIM1 for cancer diagnosis and treatment?

Authors:  Nancy S Magnuson; Zeping Wang; Gang Ding; Raymond Reeves
Journal:  Future Oncol       Date:  2010-09       Impact factor: 3.404

8.  Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.

Authors:  Tomasz Sewastianik; Maria Luisa Guerrera; Keith Adler; Peter S Dennis; Kyle Wright; Vignesh Shanmugam; Ying Huang; Helen Tanton; Meng Jiang; Amanda Kofides; Maria G Demos; Audrey Dalgarno; Neil A Patel; Anwesha Nag; Geraldine S Pinkus; Guang Yang; Zachary R Hunter; Petr Jarolim; Nikhil C Munshi; Steven P Treon; Ruben D Carrasco
Journal:  Blood Adv       Date:  2019-11-12

9.  PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis.

Authors:  James T Lim; Neha Singh; Libia A Leuvano; Valerie S Calvert; Emanuel F Petricoin; David T Teachey; Richard B Lock; Megha Padi; Andrew S Kraft; Sathish K R Padi
Journal:  Mol Cancer Ther       Date:  2020-08-04       Impact factor: 6.261

10.  AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.

Authors:  Erika K Keeton; Kristen McEachern; Keith S Dillman; Sangeetha Palakurthi; Yichen Cao; Michael R Grondine; Surinder Kaur; Suping Wang; Yuching Chen; Allan Wu; Minhui Shen; Francis D Gibbons; Michelle L Lamb; Xiaolan Zheng; Richard M Stone; Daniel J Deangelo; Leonidas C Platanias; Les A Dakin; Huawei Chen; Paul D Lyne; Dennis Huszar
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.